Stocktoria

Evolus, Inc. EOLS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-02-08 · LEI

Evolus, Inc. financials (annual)

Revenue
$0 $34.9M $56.5M $99.7M $148.6M $202.1M $266.3M $297.2M 201720182019202020212022202320242025
Net income
-$4.5M -$46.9M -$90.0M -$163.0M -$46.8M -$74.4M -$61.7M -$50.4M -$51.6M 201720182019202020212022202320242025
Free cash flow
-$13.2M -$25.7M -$93.7M -$58.7M -$33.8M -$86.5M -$34.5M -$19.5M -$45.7M 201720182019202020212022202320242025

Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$297.2M$266.3M$202.1M$148.6M$99.7M$56.5M$34.9M$0
Gross profit$197.1M$182.3M$137.6M$89.8M$26.9M$0
R&D expense$2.1M$1.7M$4.0M$6.5M$6.7M
SG&A expense$220.8M$198.0M$164.9M$141.8M$112.1M$98.2M$113.6M$29.1M
Operating income-$32.7M-$34.4M-$49.2M-$65.3M-$44.4M-$153.1M-$98.9M-$46.1M-$11.7M
Interest expense$13.8M$9.1M$1.4M$863,000$5,000
Income tax$677,000$664,000$176,000$95,000$42,000$77,000-$15.0M$65,000-$7.3M
Net income-$51.6M-$50.4M-$61.7M-$74.4M-$46.8M-$163.0M-$90.0M-$46.9M-$4.5M
EPS (diluted)$-0.80$-0.81$-1.08$-1.33$-0.94$-4.83
Operating cash flow-$42.3M-$18.0M-$34.0M-$84.9M-$33.4M-$57.9M-$93.4M-$25.7M-$13.2M
Free cash flow-$45.7M-$19.5M-$34.5M-$86.5M-$33.8M-$58.7M-$93.7M-$25.7M-$13.2M
Cash & equivalents$53.8M$87.0M$62.8M$53.9M$146.3M$102.6M$109.9M$93.2M$0
Inventory$27.0M$12.2M$11.0M$18.9M$1.8M$3.4M$6.4M$0
Total assets$225.9M$232.6M$189.0M$178.0M$257.5M$209.1M$240.4M$171.8M$152.2M
Total liabilities$249.0M$227.0M$209.7M$159.5M$175.6M$282.0M$161.0M$87.5M$227.8M
Shareholders' equity-$23.1M$5.5M-$20.7M$18.5M$81.9M-$73.0M$79.5M$84.4M-$75.5M

Growth · year-over-year

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue growth+11.6%+31.8%+36.0%+49.1%+76.3%+61.9%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.